GlassScriptPhysician profile
Ali Hassan
NPI 1396977062
$4,582.56
in general payments reported to CMS, 2019-2025
26 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $354 · 2021: $569 · 2022: $631 · 2023: $910 · 2024: $866 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.64 |
| Education | $127.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $931.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $759.14 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $498.67 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $378.39 | 2019-2025 | Jynarque |
| Amgen INC. | $226.01 | 2022-2025 | Krystexxa, Uplizna, Tavneos |
| Alexion Pharmaceuticals, INC. | $209.83 | 2019-2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $207.97 | 2022-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $195.73 | 2023-2025 | |
| Glaxosmithkline, LLC. | $181.02 | 2022-2024 | Jesduvroq, Benlysta |
| Vantive US Healthcare LLC | $144.04 | 2025 | Renal - Pd |
| Novartis Pharmaceuticals Corporation | $133.60 | 2019-2024 | |
| Lilly USA, LLC | $102.67 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $94.09 | 2021-2023 | |
| Genzyme Corporation | $92.79 | 2019-2023 | |
| Fresenius USA Marketing, INC. | $79.93 | 2019-2023 | Korsuva, Velphoro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.54 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $53.19 | 2023-2024 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $51.45 | 2020-2021 | |
| Daiichi Sankyo INC. | $39.47 | 2019-2020 | |
| Ardelyx, INC. | $32.94 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $24.69 | 2025 | |
| Apellis Pharmaceuticals, INC. | $23.48 | 2025 | Empaveli |
| Novo Nordisk INC | $21.70 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.86 | 2019 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.